Lawrence M Cher
Overview
Explore the profile of Lawrence M Cher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kong B, Sim H, Nowak A, Yip S, Barnes E, Day B, et al.
BMJ Open
. 2023 May;
11(12):e054075.
PMID: 37185327
Introduction: Grades 2 and 3 gliomas (G2/3 gliomas), when combined, are the second largest group of malignant brain tumours in adults. The outcomes for G2/3 gliomas at progression approach the...
2.
Balasubramanian A, Gunjur A, Hafeez U, Menon S, Cher L, Parakh S, et al.
Neurooncol Adv
. 2021 Feb;
3(1):vdaa171.
PMID: 33543145
Background: Improving outcomes of patients with glioblastoma (GBM) represents a significant challenge in neuro-oncology. We undertook a systematic review of key parameters of phase II and III trials in GBM...
3.
Hafeez U, Cher L
Neurooncol Adv
. 2020 Jul;
1(1):vdz013.
PMID: 32642651
Glioblastoma (GBM) is the most common primary brain neoplasm with median overall survival (OS) around 15 months. There is a dearth of effective monitoring strategies for patients with high-grade gliomas....
4.
Leimgruber A, Hickson K, Lee S, Gan H, Cher L, Sachinidis J, et al.
Eur J Nucl Med Mol Imaging
. 2020 Feb;
47(6):1476-1485.
PMID: 32025750
Introduction: Tumor hypoxia is a centerpiece of disease progression mechanisms such as neoangiogenesis or aggressive hypoxia-resistant malignant cells selection that impacts on radiotherapy strategies. Early identification of regions at risk...
5.
Field K, Phal P, Fitt G, Goh C, Nowak A, Rosenthal M, et al.
Cancer
. 2017 Jul;
123(18):3576-3582.
PMID: 28678383
Background: Bevacizumab has been associated with prolonged progression-free survival for patients with recurrent glioblastoma; however, not all derive a benefit. An early indicator of efficacy or futility may allow early...
6.
Wick W, Puduvalli V, Chamberlain M, van den Bent M, Carpentier A, Cher L, et al.
J Clin Oncol
. 2010 Feb;
28(7):1168-74.
PMID: 20124186
Purpose: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4). Patients And Methods: Patients were randomly assigned...
7.
Scott A, Lee F, Tebbutt N, Herbertson R, Gill S, Liu Z, et al.
Proc Natl Acad Sci U S A
. 2007 Mar;
104(10):4071-6.
PMID: 17360479
An array of cell-surface antigens expressed by human cancers have been identified as targets for antibody-based therapies. The great majority of these antibodies do not have specificity for cancer but...
8.
Cher L, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, et al.
J Nucl Med
. 2006 Mar;
47(3):410-8.
PMID: 16513609
Unlabelled: PET offers a noninvasive means to assess neoplasms, in view of its sensitivity and accuracy in staging tumors and potentially in monitoring treatment response. The aim of this study...
9.
Chua S, Rosenthal M, Wong S, Ashley D, Woods A, Dowling A, et al.
Neuro Oncol
. 2004 Feb;
6(1):38-43.
PMID: 14769139
Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM). Caelyx (liposomal doxorubicin) has established activity in a broad range of tumors but has not been extensively evaluated...